June 2022 - Volume 81 - 6
Editorials
1. Reflections on a contemporary European tragedy
2. Greetings from the editor
Heroes and pillars of rheumatology
3. EULAR 75-year anniversary: commentaries on key ARD papers from 1947
Views on news
4. Treatment of lupus: more options after a long wait
5. In the shadow of antibodies: how T cells defend against COVID-19
Recommendations
6. EULAR points to consider for the use of imaging to guide interventional procedures in patients with rheumatic and musculoskeletal diseases (RMDs)
7. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
8. EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology
9. EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients’ questions
Rheumatoid arthritis
10. Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries
11. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
Inflammatory arthritis
12. Ageing and interferon gamma response drive the phenotype of neutrophils in the inflamed joint
Psoriatic arthritis
13. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
14. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study
Spondyloarthritis
15. Factors predicting axial spondyloarthritis among first-degree relatives of probands with ankylosing spondylitis: a family study spanning 35 yearsEditor's Choice
Polymyalgia rheumatic
16. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial
Systemic lupus erythematosus
17. Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus
Systemic sclerosis
18. Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease
Vasculitis
19. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study
Epidemiology
20. Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort
21. Efficacy of COVID-19 vaccines in patients taking immunosuppressants
22. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases
23. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
Letters
24. Has the gout epidemic peaked in the UK? A nationwide cohort study using data from the Clinical Practice Research Datalink, from 1997 to across the COVID-19 pandemic in 2021
25. Effectiveness and safety of combined biological therapy in patients with refractory multidomain spondyloarthritis
26. Serum interferon-α levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity
27. ADAMTS5 as a therapeutic target for osteoarthritis: Mendelian randomisation study
EULAR news
28. An extraordinary 75 years of EULAR
Electronic pages
29. Error in the dosage of Methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
30. Response to: ‘Error in the dosage of methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis’ by Scheicht
31. Off-label use of tofacitinib: a potential treatment option for SAPHO syndrome
32. Response to: ‘Off-label use of tofacitinib: a potential treatment option for SAPHO syndrome’ by Xie et al
33. Comment on ‘Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis’ by Kuwabara et al
34. Response to: ‘Comment on ‘Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis’ by Kuwabara et al’ by Rios Rodriguez et al
35. Bowman’s capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications
36. Response to: ‘Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications’ by L'Imperio et al
37. Pisotriquetral arthritis: ‘forgotten’ joint in ultrasound imaging of the wrist
38. Response to: ‘Pisotriquetral arthritis: ‘forgotten’ joint in ultrasound imaging of the wrist’ by Becciolini et al
39. Comparison of MS score and HScore for the diagnosis of adult-onset Still’s disease-associated macrophage activation syndrome
40. Response to: ‘Comparison of MS score and HScore for the diagnosis of adult-onset Still’s disease associated macrophage activation syndrome’ by Zhang et al
41. Understanding bone fragility: theoretical explanation to non-physician health professionals
42. Response to: ‘Understanding bone fragility: theoretical explanation to non-physician health professionals’ by Sugiyama
43. Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease
44. Response to: ‘Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still’s disease’ by Ruscitti et al
45. Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues
46. Response to: ‘Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues’ by Ghajari and Sabour
47. Correspondence to ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’
48. Response to: ‘Correspondence to “Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’ by Ma et al
49. Correction: EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Issue Information